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Epidemiol 1995;142:91–8.ReplyTriggering of Cardiac
Arrhythmias
The Problem of Multicollinearity Among
Air Pollution and Meteorological FactorsDr. Culic suggests that the associations that we reported (1) be-
tween particulate air pollution (PM2.5) and atrial ﬁbrillation (AF)
may be confounded by inadequate control of meteorology. There
is a well-developed body of literature suggesting that acute par-
ticulate air pollution exposures can trigger cardiac events and ar-
rhythmias (2,3). There is, however, more limited evidence that
temperature and other meteorological variables can trigger such
events (4).
Dr. Culic acknowledges that the evidence of these meteoro-
logical associations is inconsistent and, in some cases, speculative,
but suggests that uncontrolled meteorological variables may be
the true causative actors. As evidence, Dr. Culic cites 4 analyses
(5–8) of Holter monitoring for a single 24-h period in up to 457
patients over 1 period (January to April) in 2001. Culic et al.
(5–8) examined the frequency of arrhythmias in each hour in
different patients versus individual characteristics plus level and
change in 8 meteorological parameters using multiple linear
regression.
In our study, 176 patients were followed for an average of 1.9
years with continuous monitoring for atrial ﬁbrillation (AF) by
implanted dual-chamber monitors. The risk of AF events associ-
ated with air pollution and meteorology were estimated using case-
crossover methods, in which the risk in the same patient is esti-
mated over time using multiple regression.
We controlled for 2 of the meteorological factors that Culic
et al. (5–8) identify as important risk factors: atmospheric tem-
perature and moisture (dew point). In their analyses, 16 meteo-
rological factors were considered, but no measures of air pollution.
Although examination of additional meteorological factors may be
marginally informative in our study, we would suggest that
assessment of air pollution in the Culic study may be even more
informative.
In terms of clinical implications, understanding the role of
meteorology in triggering acute cardiac events may help in pro-
viding guidance on activities in vulnerable patients during extreme
weather events. Understanding the cardiac risks of air pollution
exposures independent of meteorology would inform not only
vulnerable patients but also public policy in reducing population
risk (9).*Mark S. Link, MD
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Low-Density Lipoprotein
Cholesterol?
The U.S. National Cholesterol Education Program Expert Panel
on Detection, Evaluation, and Treatment of High Blood Choles-
terol in Adults recommendations (1) have had a huge impact on
the treatment of hypercholesterolemia around the world and have
had a decisive inﬂuence on all recommendations worldwide. Until
now, the recommendations were based on lowering low-density
lipoprotein cholesterol (LDL-C) as the treatment goal. The
accumulated information for more than 100 years built the “lipid
theory of atherosclerosis” (2), and the recommendations ﬁt well
with that scientiﬁc knowledge: lowering LDL-C reduces cardio-
vascular risk by reducing atherosclerosis, and LDL-C lowering is,
therefore, the objective. Over the years, as the evidence from clinical
trials has emerged, LDL-C goal levels have been reduced and thepopulation subsidiaries of reduction beneﬁt have been expanding.
The results have been dramatic and the reduction of cardiovascular
disease in many countries reﬂects this (3).
The recently published “2013 ACC/AHA Guideline on the
Treatment of Blood Cholesterol to Reduce Atherosclerotic Car-
diovascular Risk in Adults” (4) has substantially changed the
message. What is important, according to the new guideline, is to
prescribe statins, and cholesterol reduction is a consequence, not
the goal, of treatment. The guidelines have gone from a low-density
lipoprotein–focused vision to a vision focused only on statins. They
forget lipid goals, the concentration of cholesterol in the moni-
toring of patients, and, ultimately, all evidence of the pathogenesis
of atherosclerosis. The document concentrates only on 1 type of
evidence, which comes from randomized clinical trials. It should be
remembered that not all scientiﬁc evidence comes from randomized
clinical trials, and that we will never be able to have solid evidence
for many patients excluded from the trials. What are we to do
with a diabetic patient of age 60 years, with a personal history of
coronary disease and with LDL-C 130 mg/dl after maximally-
tolerated doses of statins? The document tells us to do nothing to
further reduce his LDL-C. We believe that the scientiﬁc knowl-
edge is misinterpreted, and a large group of patients is being un-
reasonably discriminated against. In contrast, the document
indicates that we should prescribe high-intensity statin treatment in
an otherwise healthy woman of 21 years, with LDL-C 190 mg/dl
and, for example, high-density lipoprotein cholesterol 90 mg/dl.
Even the document supports the use of a second or third nonstatin
lipid-lowering drug to further lower her LDL-C; however, it re-
fuses this approach to our diabetic patient.
The document has, according to the Spanish Atherosclerosis
Society, many positive aspects: the systematic review of the
literature, the deﬁnition of the groups susceptible to treatment,
the classiﬁcation of the statins’ effects, and the new calculation of
cardiovascular risk. However, the uncertainty and nihilism in many
important issues is worrisome and may harm many patients; leaving
behind the concept of intensive reduction of LDL-C will confuse
many doctors; and focusing on statins will be detrimental to the
investigation and development of other lipid-lowering drugs. For
these reasons, the Spanish Society of Arteriosclerosis does not
support this document and better recommends the guidelines
from the European Society of Cardiology/European Atherosclerosis
Society (5).*Fernando Civeira, MD, President of the Spanish
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